相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。BTN3A is a prognosis marker and a promising target for V gamma 9V delta 2 T cells based-immunotherapy in pancreatic ductal adenocarcinoma (PDAC)
Audrey Benyamine et al.
ONCOIMMUNOLOGY (2018)
Soluble PD-L1 with PD-1-binding capacity exists in the plasma of patients with non-small cell lung cancer
Masahiro Takeuchi et al.
IMMUNOLOGY LETTERS (2018)
High Serum Level of Soluble Programmed Death Ligand 1 is Associated With a Poor Prognosis in Hodgkin Lymphoma
Xiaofang Guo et al.
TRANSLATIONAL ONCOLOGY (2018)
Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations
Jun Gong et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Immune Evasion in Pancreatic Cancer: From Mechanisms to Therapy
Neus Martinez-Bosch et al.
CANCERS (2018)
PD-L1 Expression in Pancreatic Cancer
Lei Zheng
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2017)
Increased BTLA and HVEM in gastric cancer are associated with progression and poor prognosis
Xiuwen Lan et al.
ONCOTARGETS AND THERAPY (2017)
PD-L1 Expression in Pancreatic Cancer
Lei Zheng
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2017)
Serum levels of soluble programmed death protein 1 (sPD-1) and soluble programmed death ligand 1 (sPD-L1) in advanced pancreatic cancer
Stephan Kruger et al.
ONCOIMMUNOLOGY (2017)
Checkpoint Inhibitors: Applications for Autoimmunity
Anna S. Tocheva et al.
CURRENT ALLERGY AND ASTHMA REPORTS (2017)
Pancreatic ductal adenocarcinoma: State-of-the-art 2017 and new therapeutic strategies
Marta Chiaravalli et al.
CANCER TREATMENT REVIEWS (2017)
PD-1/PD-L1 and immunotherapy for pancreatic cancer
Mengyu Feng et al.
CANCER LETTERS (2017)
PD-1/PD-L1 checkpoint blockades in non-small cell lung cancer: New development and challenges
Xiangjiao Meng et al.
CANCER LETTERS (2017)
The prognostic role of desmoplastic stroma in pancreatic ductal adenocarcinoma
Lai Mun Wang et al.
ONCOTARGET (2016)
Soluble PD-L1: A biomarker to predict progression of autologous transplantation in patients with multiple myeloma
Shang-Yi Huang et al.
ONCOTARGET (2016)
BTN3A molecules considerably improve V9V2T cells-based immunotherapy in acute myeloid leukemia
Audrey Benyamine et al.
ONCOIMMUNOLOGY (2016)
From bench to bedside a comprehensive review of pancreatic cancer immunotherapy
Paul R. Kunk et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2016)
Comprehensive analyses of tumor immunity: implications for cancer immunotherapy
Bo Li et al.
GENOME BIOLOGY (2016)
The Role of Anti-PD-1/PD-L1 Agents in Melanoma: Progress to Date
Katy K. Tsai et al.
DRUGS (2015)
Immune Therapy in GI Malignancies: A Review
Judy Wang et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
BTLA marks a less-differentiated tumor-infiltrating lymphocyte subset in melanoma with enhanced survival properties
Cara L. Haymaker et al.
ONCOIMMUNOLOGY (2015)
Comparison of serum, EDTA plasma and P100 plasma for luminex-based biomarker multiplex assays in patients with chronic obstructive pulmonary disease in the SPIROMICS study
Wanda K. O'Neal et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2014)
Systemic treatment of advanced pancreatic cancer
Volker Heinemann et al.
CANCER TREATMENT REVIEWS (2012)
Analysis of serum and plasma identifies differences in molecular coverage, measurement variability, and candidate biomarker selection
Murtada Alsaif et al.
PROTEOMICS CLINICAL APPLICATIONS (2012)
The blockade of immune checkpoints in cancer immunotherapy
Drew M. Pardoll
NATURE REVIEWS CANCER (2012)
BTLA mediates inhibition of human tumor-specific CD8(+) T cells that can be partially reversed by vaccination
Laurent Derre et al.
JOURNAL OF CLINICAL INVESTIGATION (2010)
High Expression of the Inhibitory Receptor BTLA in T-Follicular Helper Cells and in B-Cell Small Lymphocytic Lymphoma/Chronic Lymphocytic Leukemia
Hasni M'Hidi et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2009)
分享论文
